Sarepta Therapeutics's total assets for Q2 2026 were $3.19B, an increase of 0.30% from the previous quarter. MX:SRPT total liabilities were $1.66B for the fiscal quarter, a -0.78% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.